Companies ›Healthcare ›ALEMG.PA

ALEMG.PA — Euronext Paris Medical Equipment, Supplies & Distribution

Laboratoires Euromedis SA

€5,00

Open in Charts → Attach watcher ⌖

— —

EUR

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

—

Op margin

—

ROE

—

Net margin

—

Debt / equity

—

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

Laboratoires Euromedis SA operates in the Healthcare Services & Equipment sector, specializing in Medical Equipment, Supplies & Distribution.

Business. Laboratoires Euromedis SA (ALEMG.PA) is a healthcare company operating in the medical equipment, supplies, and distribution industry. The firm is headquartered in France and is primarily listed on the Euronext Paris exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification92 %

SectorHealthcare

Business sectorHealthcare Services & Equipment

IndustryMedical Equipment, Supplies & Distribution

ActivityHealthcare Services & Equipment

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership

—

not yet wired

Profitability

—

not yet wired

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning ALEMG.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to ALEMG.PA. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Laboratoires Euromedis SA (ALEMG.PA) is a healthcare company operating in the medical equipment, supplies, and distribution industry. The firm is headquartered in France and is primarily listed on the Euronext Paris exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification92 %

SectorHealthcare

Business sectorHealthcare Services & Equipment

IndustryMedical Equipment, Supplies & Distribution

ActivityHealthcare Services & Equipment

AI synthesis

GENERATED

Laboratoires Euromedis SA has a basic and diluted share count of 2,844,222, indicating no dilution from stock options or convertible securities. The company's liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in the source documents.

The company reported a loss per share of -1.66 EUR and revenue of 58,696,000 EUR in the latest period. These figures suggest a challenging profitability environment, with the company currently operating at a loss. The absence of valuation snapshot data prevents a direct comparison with industry medians for profitability and returns.

There is no detailed information on the company's segments or geographic exposure, which limits the ability to assess revenue concentration or diversification. The lack of segmental data also hinders the evaluation of the company's growth trajectory and the contribution of different business lines to overall performance.

The company's risk assessment indicates a low dilution risk, but the liquidity risk remains unknown. The absence of balance-sheet inputs and no going-concern language in the source documents suggests that the company's financial health and liquidity position are not transparent.

There are no recent events or filings mentioned in the provided data that would indicate significant changes in the company's operations or financial status.

Key takeaways

The company is currently reporting a loss per share of -1.66 EUR.
Revenue for the latest period is 58,696,000 EUR.
There is no dilution from stock options or convertible securities.
The company's liquidity risk could not be assessed due to the absence of balance-sheet inputs.
The company's segments and geographic exposure are not detailed in the provided data.
**margin_outlook_rationale**: The company's current loss per share indicates a negative margin outlook, driven by operational inefficiencies or high costs.
**rd_outlook_rationale**: No information is available to assess the outlook for research and development activities.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Annual

ANNUALFiled 2023-06-23

FY 2023 · Full-year highlights

Revenue €40.8M, +12,7% YoY.

Revenue€40.8M+12,7 % YoY

Operating income—

Net income—

Free cash flow—

EPS—

Operating cash flow—

Financials

Income statement

Revenue€40.8M

Gross profit—

Operating income—

Net income—

Highlights

▍Revenue €40.8M, +12,7% YoY

Valuation FY

Market price

€5,00

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

—

Net cashⓘ

—

Current ratioⓘ

—

Debt / equityⓘ

—

ROAⓘ

—

ROEⓘ

—

Cash conversionⓘ

—

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskUnknown

Benchmarks vs cohort

No cohort benchmark data available for this issuer yet.

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic

Source documents

Laboratoires Euromedis SA Market data — financials · 2026-05-27
Laboratoires Euromedis SA Market data — analyst estimates · 2026-05-27

Ownership & reference

Leadership

Mathieu RoturierChairman of the Board, Chief Executive Officer

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

ALEMG.PACanonical

Euronext Paris · EUR

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskUnknown

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

2026-06-20 00:43 UTCANALYSTAnalyst coverage initiated

2023-06-23 10:22 UTCEARNINGSAnnual results — FY 2023 Revenue EUR 40.8M

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Leadership

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread